Analyst Ratings For NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE)
.
Some recent analyst ratings include
- 6/4/2018-JPMorgan Chase & Co. was Downgraded by analysts at JPMorgan Chase & Co. from a “Overweight ➝ Neutral” rating to a “” rating. They now have a $12.00 price target on the stock.
- 5/31/2018-Wells Fargo & Co Reiterated Rating of Market Perform.
- 6/9/2017-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE)
NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE) has insider ownership of 43.97% and institutional ownership of 91.55%.
- On 3/15/2018 Barbara Gayle Duncan, Director, sold 2,000 with an average share price of $28.11 per share and the total transaction amounting to $56,220.00.
- On 3/8/2018 Elizabeth Trehu, Insider, sold 4,545 with an average share price of $25.06 per share and the total transaction amounting to $113,897.70.
- On 3/8/2018 Kimberlee C Drapkin, CFO, sold 5,267 with an average share price of $25.01 per share and the total transaction amounting to $131,727.67.
- On 3/8/2018 Richard /Ca/ Murray, CEO, sold 16,334 with an average share price of $25.10 per share and the total transaction amounting to $409,983.40.
- On 3/5/2018 Elizabeth Trehu, Insider, sold 4,545 with an average share price of $21.50 per share and the total transaction amounting to $97,717.50.
- On 3/5/2018 Kimberlee C Drapkin, CFO, sold 5,267 with an average share price of $21.42 per share and the total transaction amounting to $112,819.14.
- On 3/5/2018 Richard /Ca/ Murray, CEO, sold 16,334 with an average share price of $21.43 per share and the total transaction amounting to $350,037.62.
Recent Trading Activity for NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE)
Shares of NASDAQ:JNCE – Jounce Therapeutics closed the previous trading session at 7.06 down -4.17 37.13% with 8.899999618530273 shares trading hands.